Navigation Links
ETHEX Corporation Issues Nationwide Voluntary Recall of Products
Date:1/28/2009

ST. LOUIS, Jan. 28 /PRNewswire-FirstCall/ -- ETHEX Corporation, a subsidiary of KV Pharmaceutical (NYSE: KVa/KVb), is issuing, as previously disclosed by KV Pharmaceutical Company on January 26, 2009, a nationwide voluntary recall of the products identified below (all lots within their expiration dates) at a wholesale or a retail level as a precautionary measure because they may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practices (cGMPs). Some of these products have had specific lots recalled earlier due to defects found, including oversized tablets delivering higher than labeled doses. These additional products are being removed to assure that no other defective products remain in the marketplace.

Patients who may have these medicines in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medication may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

    Products Recalled to WHOLESALE Level:

    Amlodipine Besylate Tablets, 10mg (58177-538-26 & 538-11)
    Amlodipine Besylate Tablets, 2.5mg (58177-536-26)
    Amlodipine Besylate Tablets, 5mg (58177-537-26, 537-07 & 537-11)
    Benazepril HCl Tablets, 10mg (58177-342-04 & 342-08)
    Benazepril HCl Tablets, 20mg (58177-343-04 & 343-08)
    Benazepril HCl Tablets, 40mg, (58177-344-04 & 344-08)
    Benazepril HCl Tablets, 5mg (58177-341-04)
    Benzonatate Capsules, 100mg (58177-091-04 & 091-08)
    Benzonatate Capsules, 200mg (58177-092-04 & 092-08)
    Bromfenex ER Capsules (58177-019-04)
    Bromfenex PD ER Capsules (58177-020-04)
    Buspirone HCl Tablets, 10mg (58177-265-04 & 265-08)
    Buspirone HCl Tablets, 15mg (58177-309-04 & 309-08)
    Buspirone HCl Tablets, 5mg (58177-264-04 & 264-08)
    Codeine Phosphate/Guaifenesin Tablets, 10mg (58177-223-04)
    Dextroamphetamine Sulfate Tablets, 10mg (58177-312-04)
    Dextroamphetamine Sulfate Tablets, 5mg (58177-311-04)
    Dextroamphetamine Tablets, 10mg (58177-312-04)
    Diltiazem HC1 Capsules, 120mg (58177-061-11)
    Diltiazem HC1 Capsules, 120mg (58177-061-19 & 061-26)
    Diltiazem HC1 Capsules, 180mg (58177-062-09 & 062-11)
    Diltiazem HC1 Capsules, 180mg (58177-062-19 & 062-26)
    Diltiazem HC1 Capsules, 240mg (58177-063-09 & 063-11)
    Diltiazem HC1 Capsules, 240mg (58177-063-19 & 063-26)
    Diltiazem HC1 Capsules, 300mg (58177-064-19 & 064-26)
    Diltiazem HC1 Capsules, 360mg (58177-065-09 & 065-11)
    Diltiazem HC1 Capsules, 360mg (58177-065-19 & 065-26)
    Diltiazem HC1 Capsules, 420mg (58177-066-09 & 066-11)
    Diltiazem HC1 Capsules, 420mg (58177-066-19 & 066-26)
    Disopyramide Phosphate ER Capsules, 150mg (58177-002-04)
    Doxazosin Mesylate Tablets, 1mg (58177-266-04 & 266-08)
    Doxazosin Mesylate Tablets, 2mg (58177-267-04 & 267-08)
    Doxazosin Mesylate Tablets, 4mg (58177-268-04 & 268-08)
    Doxazosin Mesylate Tablets, 8mg (58177-269-04 & 269-08)
    Ethedent Chewable Tablets, .25mg (58177-432-40)
    Ethedent Chewable Tablets, .5mg (58177-433-40 & 433-09)
    Ethedent Chewable Tablets, 1mg (58177-434-40 & 434-09)
    EthexDerm BPW-10, 10% (58177-929-65)
    EthexDerm BPW-5, 5% (58177-928-65)
    Ethezyme 650 (58177-868-02)
    Ethezyme 830 Papain-Urea (58177-816-02)
    Ethezyme Papain-Urea (58177-804-02)
    ETH-Oxydose Concentrated Solution (58177-914-04 & 914-56)
    Guaifenex DM ER Tablets (58177-213-04)
    Guaifenex GP ER Tablets (58177-373-04)
    Guaifenex PSE 120 ER Tablets (58177-208-04)
    Guaifenex PSE 60 ER Tablets (58177-214-04)
    Guaifenex PSE 80 Tablets (58177-413-04)
    Guaifenex PSE 85 Tablets (58177-478-04)
    Hista-Vent DA Tablets (58177-227-04)
    Hista-Vent PSE tablets (58177-426-04)
    Histinex HC Liquid (58177-877-07 & 877-12)
    Histinex PV Liquid (58177-883-07)
    Hydrocodone Bitartrate & Acetaminophen Liquid (58177-909-07)
    Hydrocodone Bitartrate/Guaifenesin Liquid (58177-881-07)
    Hydrocortisone and Iodoquinol Cream, 1% (58177-803-02)
    Hydroquinone 4% Cream w/SS, 1oz. (58177-802-02)
    Hydroquinone 4% Cream, 1oz. (58177-801-02)
    Hydro-Tussin CBX Liquid (58177-924-07)
    Hydro-Tussin DHC Syrup (58177-926-07)
    Hydro-Tussin DM Liquid (58177-906-07)
    Hydro-Tussin EXP Liquid (58177-927-07)
    HydroTussin HC Syrup (58177-915-07)
    Hydro-Tussin Liquid (58177-890-07)
    Hydro-Tussin XP Liquid (58177-916-07)
    Hyoscyamine Orally Disintegrating Tablets, .125mg (58177-423-04)
    Hyoscyamine Sublingual Tablets, .125mg (58177-255-04)
    Hyoscyamine Sulfate ER   Tablets, .375mg (58177-237-04)
    Hyoscyamine Sulfate ER Capsules, .375mg (58177-017-04)
    Hyoscyamine Sulfate Oral Tablets, .125mg (58177-274-04)
    Isosorbide Mononitrate ER Tablets, 120mg (58177-201-04)
    Isosorbide Mononitrate ER Tablets, 30mg (58177-222-04, 222-08 & 222-11)
    Isosorbide Mononitrate ER Tablets, 60mg (58177-238-04, 238-08 & 238-11)
    Meperidine/Promethazidne Capsules (58177-027-04)
    Morphine InveAmp, 20mg x 1mL (58177-886-56)
    Morphine InveAmp, 5mg/.25mL (58177-888-80)
    Morphine Sulfate Concentrated Oral Solution 20mg/1ml (58177-886-01,
     886-03 &886-05)
    Morphine Sulfate Concentrated Oral Solution, 20mg/1ml (58177-886-57)
    Morphine Sulfate ER Tablets, 100mg (58177-340-04)
    Morphine Sulfate ER Tablets, 15mg (58177-310-04)
    Morphine Sulfate ER Tablets, 200mg (58177-380-04)
    Morphine Sulfate ER Tablets, 30mg (58177-320-04)
    Morphine Sulfate ER Tablets, 60mg (58177-330-04)
    Morphine Sulfate IR Tablets, 15mg (58177-313-04)
    Morphine Sulfate IR Tablets, 30mg (58177-314-04)
    NitroQuick Sublingual Tablets, .3mg (58177-323-04)
    NitroQuick Sublingual Tablets, .4mg (58177-324-18 & 324-04)
    NitroQuick Sublingual Tablets, .6mg (58177-325-04)
    Nystatin Topical Powder, USP 15 grams (58177-839-45)
    Nystatin Topical Powder, USP 30 grams (58177-839-46)
    Nystatin Topical Powder, USP 60 grams (58177-839-61)
    Ondansetron Orally Disintegrating Tablets, 4mg (58177-363-22)
    Ondansetron Orally Disintegrating Tablets, 8mg (58177-364-22 & 364-56)
    Oxycodone HCl Capsules, 5mg (58177-041-04 & 041-11)
    Oxycodone HCl IR Tablets, 10mg (58177-461-04)
    Oxycodone HCl IR Tablets, 15mg, (58177-445-04)
    Oxycodone HCl IR Tablets, 20mg (58177-462-04)
    Oxycodone HCl IR Tablets, 30mg (58177-446-04)
    Oxycodone HCl IR Tablets, 5mg (58177-625-04 & 625-11)
    Pangestyme CN20 (58177-030-04)
    Pangestyme CN10 (58177-029-04)
    Pangestyme EC100 (58177-031-04)
    Pangestyme EC250 (58177-031-06)
    Pangestyme MT16 (58177-028-04)
    Pangestyme UL12 (58177-048-04)
    Pangestyme UL18 (58177-049-04)
    Pangestyme UL20  (58177-050-04)
    PhenaVent Capsules (58177-078-19)
    PhenaVent D Tablets (58177-444-04)
    PhenaVent LA Capsules (58177-095-19)
    PhenaVent PED Capsules (58177-079-04)
    Plaretase 800 (58177-416-04 & 416-08)
    Potassium Chloride ER Capsules, 10mEq (58177-001-04, 001-08, 001-09, &
     001-11)
    Potassium Chloride ER Capsules, 8mEq (58177-677-04 & 677-08)
    Potassium Chloride ER Tablets, 20mEq (58177-202-04, 202-08, 202-09 &
     202-11)
    Prednisolone Sodium Oral Solution (58177-932-05)
    Prednisolone Syrup 15mg/5mL (58177-910-05 & 910-07)
    Prednisolone Syrup 5mg/5mL (58177-912-03)
    Propafenone HCl Tablets, 150mg (58177-331-04 & 331-11)
    Propafenone HCl Tablets, 225mg (58177-332-04)
    Propafenone HCl Tablets, 300mg (58177-333-04)
    Pseudovent 400 Capsules (58177-096-04)
    Pseudovent Capsules (58177-045-04)
    Pseudovent PED Capsules (58177-046-04)
    Tri-Vent DM Syrup (58177-925-07)
    Tri-Vent DPC Liquid (58177-923-07)
    Tri-Vent HC Liquid (58177-920-07)

    Products Recalled to RETAIL PHARMACY Level:

    Hydromorphone HCl Tablets, 2mg (58177-620-04 & 620-11)
    Hydromorphone HCl Tablets, 4mg (58177-621-04 & 621-11)
    Hydromorphone HCl Tablets, 8mg (58177-449-04)
    Metoprolol Succinate ER Tablets, 50mg (58177-369-04, 369-09 & 369-11)
    Metoprolol Succinate ER Tablets, 100mg (58177-368-04, 368-09 & 368-11)
    Metoprolol Succinate ER Tablets, 25mg (58177-293-04, 293-09 & 293-11)
    Metoprolol Succinate ER Tablets, 200mg (58177-358-04, 358-09 & 358-11)

Any wholesale or retail customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, faxed to ETHEX Customer Service at 314-646-3788, or e-mailed to customer-service@ethex.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

ETHEX Corporation has initiated recall notifications to wholesalers (and to retailers for Hydromorphone HCl and Metoprolol Succinate only) nationwide who received any inventory of the recalled products with instructions for returning the recalled products. Patients with questions about the recall should call the telephone number above, or contact their health-care providers.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the company is unable to determine when distribution of these products will resume.

Any adverse reactions experienced with the use of these products should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at http://www.fda.gov/medwatch.

The recall announcement is posted on http://www.kvpharma.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE KV Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. BioElectronics Corporation Announces Singapore and Malaysia Sales
7. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
8. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
9. Insulet Corporation to Present at the Thomas Weisel Partners Healthcare Conference on September 6, 2007
10. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
11. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DUBLIN , Feb. 16, 2017 ... the "Synthetic Biology: Global Markets" report to ... ... synthetic-biology products (synthetic genes, biobrick parts, delivery plasmids, chassis ... DNA synthesis and assembly, genome editing, bioinformatics and specialty ...
(Date:2/16/2017)... Feb. 16, 2017 UCHealth ( Aurora, ... LungDirect for pulmonary nodule patient management. In addition to ... a spot on the lung, UCHealth looks to improve ... data entry. Stephanie Brown, RN , ... nodule patients with an Excel spreadsheet, which was extremely ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive ... Chief Commercial Officer with GenePeeks. Matt is a veteran life sciences and ... computational genomics company focused on identifying inherited disease risk in future generations. In ...
Breaking Biology Technology:
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)...  EyeLock LLC, a market leader of iris-based identity ... What You Should Know About Biometrics in the Cloud ... is a growing concern. In traditional schemes, cryptography is ... authentication schemes such as username/password suffer from inherent weaknesses. ... an elegant solution to the problem of high-security user ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):